Data from FDA - Curated by EPG Health - Last updated 01 September 2017


INDICATIONS AND USAGE Gabapentin capsules, USP are indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Allergic Rhinitis

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

+ 4 more

Anticoagulation Therapy for Stroke Prevention

Anticoagulation Therapy for Stroke Prevention

Anticoagulation therapy for Stroke Prevention Learning Zone offers a deep-dive into atrial fibrillation causes, consequences, diagnosis and management to help you deliver optimal care and prevent strokes in patients living with this common arrhythmia.

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Load more

Related Content

Advisory information

CONTRAINDICATIONS Gabapentin capsules, USP are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.
Adverse reactions
ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Anaphylaxis and Angioedema Withdrawal Precipitated Seizure, Status Epilepticus Suicidal Behavior and Ideation Neuropsychiatric Adverse Reactions (Pediatric Patients 3 to 12 Years of Age) Sudden and Unexplained Death in Patients with Epilepsy 1. Clinical Trials Experience

Usage information

Dosing and administration
Use in special populations



More information

Category Value
Orphan designation No
Product NDC 69677-069
Date Last Revised 17-08-2017
RXCUI 1099896
List of excipients INACTIVE INGREDIENT aqua (deionized water), arnica montana flowe rextract, C13-14 isoparaffin, cetearyl alcohol, chondroitin sulfate, emu oil, ethylhexylglycerin, glucosamine sulfate, glycerin, glyceryl stearate, laureth-7, methylsulfonylmethane (MSM), PEG-100 stearate, phenoxyethanol, polyacrylamide, propylene glycol, stearic acid, triethanolamine, urea.
Marketing authorisation holder MAS Management Group Inc